Novartis, Molecular Partners report positive early-stage results of COVID-19 antiviral therapy, ensovibep

seekingalpha2021-03-09

Molecular Partners(OTCPK:MLLCF)and itscollaboratorNovartis(NYSE:NVS)announced initial results from their ongoing phase 1 study of first tri-specificCOVID-19 antiviral treatment, ensovibep (MP0420), in...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment
2